Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes

NCT00411892 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00411892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00411892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Terminated
Start date
November 29, 2006
Completion date
March 18, 2008
Enrollment
196 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2